4 stories mentioning HKG:3692Updated 5d ago
Every FINWIRES story that references HKG:3692, newest first.
Hansoh Pharmaceutical's (HKG:3692) new drug application for HS-10568 Injection was accepted by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The acceptance is for use of the drug secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing hemodialysis.
Hansoh Pharmaceutical (HKG:3692) said China's National Medical Products Administration accepted its application of olatorepatide injection to treat obesity, according to a Thursday filing with the Hong Kong bourse.The drug is meant to be administered once a week.Shares of the company fell nearly 1% in recent morning trade.
Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.Shares of the pharma firm were down over 1% in Thursday afternoon trading.The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.
Hansoh Pharmaceutical's (HKG:3692) HS-20093 for injection in combination with adebrelimab obtained approval to be included as a Breakthrough Therapy Designated Drug from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval is for the indication of locally advanced or metastatic non-small cell lung cancer.
